MHRA approves teplizumab to delay progression of type 1 diabetes
Type 1 diabetes (T1D) research is at a pivotal point – there is now a licensed therapy in the UK, Teplizumab, to delay onset of symptoms in people with early stage T1D (Link).
Over decades, our UK-based research, both academic and commercial has made a major contribution to identifying children and adults who will develop type 1 diabetes symptoms in the future (Link to studies).
There is now one treatment to delay, but additional research will identify even better treatments leading to our vision of insulin free type 1 diabetes.
